- Home
- IONS vs CALM Comparison
IONS vs CALM Comparison
Compare IONS & CALM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CALM
- Stock Information
- Founded
- IONS 1989
- CALM 1957
- Country
- IONS United States
- CALM United States
- Employees
- IONS N/A
- CALM N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CALM Farming/Seeds/Milling
- Sector
- IONS Health Care
- CALM Consumer Staples
- Exchange
- IONS Nasdaq
- CALM Nasdaq
- Market Cap
- IONS 6.0B
- CALM 5.0B
- IPO Year
- IONS 1991
- CALM 1996
- Fundamental
- Price
- IONS $31.43
- CALM $113.63
- Analyst Decision
- IONS Buy
- CALM Sell
- Analyst Count
- IONS 18
- CALM 3
- Target Price
- IONS $62.00
- CALM $66.33
- AVG Volume (30 Days)
- IONS 1.5M
- CALM 784.2K
- Earning Date
- IONS 02-19-2025
- CALM 01-07-2025
- Dividend Yield
- IONS N/A
- CALM 3.76%
- EPS Growth
- IONS N/A
- CALM 38.89
- EPS
- IONS N/A
- CALM 12.86
- Revenue
- IONS $803,067,000.00
- CALM $3,084,407,000.00
- Revenue This Year
- IONS N/A
- CALM $21.60
- Revenue Next Year
- IONS $10.85
- CALM N/A
- P/E Ratio
- IONS N/A
- CALM $8.84
- Revenue Growth
- IONS 30.57
- CALM 15.57
- 52 Week Low
- IONS $31.41
- CALM $53.59
- 52 Week High
- IONS $52.49
- CALM $114.38
- Technical
- Relative Strength Index (RSI)
- IONS 33.19
- CALM 67.23
- Support Level
- IONS $32.61
- CALM $101.46
- Resistance Level
- IONS $35.37
- CALM $112.53
- Average True Range (ATR)
- IONS 1.28
- CALM 3.80
- MACD
- IONS -0.30
- CALM 0.68
- Stochastic Oscillator
- IONS 0.36
- CALM 95.21
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About CALM Cal-Maine Foods Inc.
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.